Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)
- 413 Downloads
In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially compromises cancer control.
We conducted a 6-week phase II single-arm trial of PAL, a second-generation 5-HT3RA antiemetic, for cRINV prevention in MG patients receiving radiation therapy (RT; 54–60 Gy) and concomitant daily temozolomide (TMZ; 75 mg/m2/dX42d). Each week before radiation, patients received single-dose palonosetron (PAL) 0.25 mg IV (total = 6 doses). With safety/tolerability as the primary endpoint, the study was designed to differentiate between toxicity rates of 25 % (unacceptable) and 10 % (acceptable) toxicity rates. Secondary endpoints included the percentage of patients achieving cRINV complete response (CR: no emesis or rescue antiemetic) and QoL. Patients reported adverse effects in Common Toxicity Criteria for Adverse Events diaries; recorded vomiting, nausea, and rescue medication use in diaries (which were used to assess cRINV-CR); and reported QoL 4 days/week using the Modified Functional Living Index-Emesis (M-FLIE) and Osoba nausea and vomiting/retching modules.
We enrolled 38 patients (mean age 59 years, 55 % female, 95 % white, 68 % used oral corticosteroids, 76 % reported low alcohol use). Four patients (10.5 %) experienced unacceptable treatment-related toxicity, defined as any grade 3, 4, or 5 non-hematologic toxicity. M-FLIE and Osoba scores showed no evidence of treatment impact on QoL. Overall, cRINV-CR rates for 6 weeks ranged from 67–79 %.
Single-dose weekly PAL is a safe and tolerable antiemetic for cRINV prevention in MG patients receiving standard RT and concomitant TMZ.
KeywordsChemotherapy Nausea Emesis Radiation-induced nausea and vomiting Safety Efficacy Supportive care Antiemetic guidelines Evidence-based practice Gliomas
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Eisai pharmaceutical has supported this investigator initiated IRB approved study.
- 2.Parisi S, Corsa P, Raguso A, Perrone A, Cossa S, Munafo T, Sanpaolo G, Donno E, Clemente MA et al (2015) Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. Biomed Res Int 2015:620643. doi: 10.1155/2015/620643 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.National Comprehensive Cancer Network [NCCN]. (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): central nervous system cancers. Version 1.2015. Fort Washington, PA: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed June 26, 2015
- 9.Dennis K, Zhang L, Lutz S, van Baardwijk A, van der Linden Y, Holt T, Arnalot PF, Lagrange JL, Maranzano E et al (2012) International patterns of practice in the management of radiation therapy-induced nausea and vomiting. Int J Radiat Oncol Biol Phys 84(1):e49–60. doi: 10.1016/j.ijrobp.2012.02.031 CrossRefPubMedGoogle Scholar
- 10.Salvo N, Doble B, Khan L, Amirthevasar G, Dennis K, Pasetka M, Deangelis C, Tsao M, Chow E (2012) Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys 82(1):408–17. doi: 10.1016/j.ijrobp.2010.08.060 CrossRefPubMedGoogle Scholar
- 11.Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–43. doi: 10.1093/annonc/mdq194 CrossRefPubMedGoogle Scholar
- 12.Gralla RJ, Roila F, Tonato M, Herrstedt J, for Multinational Association of Supportive Care in Cancer [MASCC]. (2013) MASCC/ESMO Antiemetic Guideline 2013. Multinational Association of Supportive Care in Cancer [MASCC]. http://www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_english_2014.pdf. Accessed June 12, 2015
- 13.Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–98. doi: 10.1200/jco.2010.34.4614 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Maranzano E, De Angelis V, Pergolizzi S, Lupattelli M, Frata P, Spagnesi S, Frisio ML, Mandoliti G, Malinverni G et al (2010) A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94(1):36–41. doi: 10.1016/j.radonc.2009.11.001 CrossRefPubMedGoogle Scholar
- 18.National Comprehensive Cancer Network [NCCN]. (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis. Version 1.2015. Fort Washington, PA: National Comprehensive Cancer Network; 2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed June 12, 2015
- 19.Merck Sharp & Dohme Corp. (2014) Highlights of prescribing information.Temodar® (temozolomide) Capsules, Temodar® (temozolomide) for injection. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022277s008lbl.pdf Accessed June 30, 2015
- 21.Rozzi A, Nardoni C, Corona M, Restuccia MR, Fabi A, Bria E, Minniti G, Lanzetta G (2011) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer 19(5):697–701. doi: 10.1007/s00520-010-0893-y CrossRefPubMedGoogle Scholar
- 24.Popovic M, Warr DG, Deangelis C, Tsao M, Chan KK, Poon M, Yip C, Pulenzas N, Lam H et al (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22(6):1685–97. doi: 10.1007/s00520-014-2175-6 CrossRefPubMedGoogle Scholar
- 26.Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19(6):823–32. doi: 10.1007/s00520-010-0908-8 CrossRefPubMedGoogle Scholar
- 27.Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D (2014) Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22(2):469–77. doi: 10.1007/s00520-013-1999-9 CrossRefPubMedGoogle Scholar
- 28.National Cancer Institute Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program. (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed June 27, 2015
- 30.Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11(8):522–7. doi: 10.1007/s00520-003-0482-4 CrossRefPubMedGoogle Scholar